The safety profile presented as follows is based on data from more than 5300 subjects.
Frequencies are reported as: Very common: (≥1/10); Common: (≥1/100, <1/10); Uncommon: (≥1/1,000, <1/100); Rare: (≥1/10,000, <1/1,000); Very rare: (<1/10,000) including isolated reports. (See Table 5.)
Click on icon to see table/diagram/image
In a comparative trial in subjects from 11 years up to and including 15 years of age, the incidence of local and general solicited symptoms reported after a two-dose regimen of Engerix-B 20 μg was similar overall to that reported after the standard three-dose regimen of Engerix-B 10 μg.